Status:

COMPLETED

ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

Lead Sponsor:

Alkermes, Inc.

Conditions:

Alcohol Dependence

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study will evaluate the safety and efficacy of ALKS33 (RDC-0313) compared with placebo in adults with alcohol dependence. There will be 11 study visits conducted over a period of about 4 months. ...

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled study. A 3-stage adaptive design will be used. Following screening, eligible subjects will be randomized equally to 1 of 4 groups (...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Current diagnosis of alcohol dependence, with recent heavy drinking (eg, 5 drinks per day for men and 4 drinks per day for women)
  • A noncustodial stable residence and a telephone
  • Women having reproductive potential must agree to use an approved method of contraception for the duration of the study
  • Ability to stop drinking prior to receiving study drug

Exclusion

  • Pregnancy and/or current breastfeeding
  • Past or present history of an AIDS-indicator disease
  • Current dependence on any drugs (exclusive of nicotine, caffeine, or alcohol)
  • Positive urine drug screen for benzodiazepines (unless used for a short-term basis during alcohol detoxification), opioids, amphetamines/ methamphetamines or cocaine at Visits 1 and 2
  • Clinically significant medical condition
  • Current or anticipated need for prescribed opioid medication during the study period
  • Use of naltrexone within 60 days prior to screening
  • Current need for antidepressants (within 30 days prior to entry)
  • Participation in a clinical trial of a pharmacological agent within 30 days prior to screening
  • Parole or probation or pending legal proceedings that have the potential for incarceration during the study period

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2010

Estimated Enrollment :

406 Patients enrolled

Trial Details

Trial ID

NCT00981617

Start Date

October 1 2009

End Date

August 1 2010

Last Update

August 23 2011

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

Alkermes Investigational Site

Tucson, Arizona, United States, 85712

2

Alkermes Investigational Site

Cerritos, California, United States, 90703

3

Alkermes Investigational Site

Oceanside, California, United States, 92056

4

Alkermes Investigational Site

Pico Rivera, California, United States, 90660